Back to search

Article

A double-hit <i>in vivo</i> model of <i>GBA1</i> viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration

2021-06-23

Abstract excerpt

Preclinical and clinical studies support a strong association between mutations in the GBA1 gene that encodes β-glucocerebrosidase (GCase) (EC 3.2.1.45; glucosylceramidase beta) and Parkinson’s disease (PD). Alpha-synuclein (AS), a key player in PD pathogenesis, and GBA1 mutations may independently and synergistically cause lysosomal dysfunction and thus, embody clinically well-validated targets of the neurodege...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
17521e21-11d2-5ce4-a2e1-b18169fdeb81
DOI
10.1101/2021.06.23.449545
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A double-hit <i>in vivo</i> model of <i>GBA1</i> viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degenerationDOI 10.1101/2021.06.23.449545
A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degenerationSemantic proximity
A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.Semantic proximity
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.Semantic proximity
AAV delivery of <i>GBA1</i> suppresses α-synuclein accumulation in Parkinson’s disease models and restores motor dysfunction in a Gaucher’s disease modelSemantic proximity
A human <i>GBA-L444P</i> transgene drives early and persistent dopamine neurotransmission deficits and alpha-synuclein pathology in a mouse model of early Parkinson’s diseaseSemantic proximity
Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques.Semantic proximity
GBA1-Associated Parkinson's Disease Is a Distinct Entity.Semantic proximity
The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.Semantic proximity
Linking <i>Gba1</i> E326K mutation to microglia activation and mild age-dependent dopaminergic NeurodegenerationSemantic proximity
Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegenerationSemantic proximity
Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.Semantic proximity
AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson’s disease models and restores functions in Gaucher’s disease modelsSemantic proximity
Select a neighboring publication to make it the new centre.